A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma
View/ Open
13249 3547.full.pdf (117.2Kb)
Access Status
Full text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.Author
Bertrand, Kimberly A.
Birmann, Brenda M.
Chang, Ellen T.
Spiegelman, Donna
Aster, Jon C.
Zhang, Shumin M.
Laden, Francine
Published Version
https://doi.org/10.1182/blood-2010-05-282715Metadata
Show full item recordCitation
Bertrand, K. A., B. M. Birmann, E. T. Chang, D. Spiegelman, J. C. Aster, S. M. Zhang, and F. Laden. 2010. “A Prospective Study of Epstein-Barr Virus Antibodies and Risk of Non-Hodgkin Lymphoma.” Blood 116 (18): 3547–53. https://doi.org/10.1182/blood-2010-05-282715.Abstract
Severe immunosuppression is an established risk factor for non-Hodgkin lymphoma (NHL), but an association with subclinical immune dysfunction is unclear. We conducted a case-control study nested in the Physicians' Health Study and the Nurses' Health Study cohorts to determine whether patterns of antibody response to Epstein-Barr virus (EBV) were associated with NHL risk. We measured antibody titers against viral capsid antigen, early antigen, and Epstein-Barr nuclear antigen (EBNA-1 and EBNA-2) in blood samples collected before diagnosis from 340 cases and 662 matched controls. Using conditional logistic regression, we estimated rate ratios (RRs) and 95% confidence intervals (CIs) for elevated versus normal titers and the ratio of anti-EBNA-1 to anti-EBNA-2 titers (<= 1.0 vs > 1.0). We found no association between EBV serostatus, elevated titers, or an EBNA-1/EBNA-2 ratio <= 1.0 and NHL risk overall. For chronic lymphocytic leukemia/small lymphocytic lymphoma, suggestive associations were noted for elevated anti-EBNA-2 (RR, 1.74; 95% CI, 0.99-3.05), anti-viral capsid antigen ( RR, 1.58; 95% CI, 0.79-3.14), and EBNA-1/EBNA-2 ratio <= 1.0 ( RR, 1.52; 95% CI, 0.91-2.55). There was no evidence of heterogeneity by subtype. Overall, we found no evidence that EBV antibody profile predicts NHL risk in immunocompetent persons, with the possible exception of chronic lymphocytic leukemia/small lymphocytic lymphoma. (Blood. 2010;116(18):3547-3553)Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41384742
Collections
- SPH Scholarly Articles [6392]
Contact administrator regarding this item (to report mistakes or request changes)